Latanoprost Biogaran (Latanoprost)

Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the ciliary body. This binding remodels the extracellular matrix, increasing uveoscleral outflow of aqueous humor, which in turn reduces intra‑ocular pressure and provides therapeutic benefit in glaucoma and ocular hypertension.

The dosing regimen for Latanoprost Biogaran is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily, usually in the evening, but the exact dose and frequency should follow the prescriber’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The most common alternative class is beta‑blocker eye drops such as timolol. Latanoprost typically offers once‑daily dosing and a favorable side‑effect profile, whereas beta‑blockers may require multiple daily doses and can affect systemic cardiovascular function. Choice depends on patient tolerance, comorbidities and physician preference.

Latanoprost Biogaran should be stored at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not refrigerate unless specifically instructed by the manufacturer.

Administer one drop of Latanoprost Biogaran into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. Ensure the dropper does not touch the eye or surrounding tissues, and avoid wearing contact lenses for at least 15 minutes after instillation.

Serious but rare risks include severe allergic reactions, uveitis or iritis, macular edema, paradoxical increase in intra‑ocular pressure, corneal thinning or ulceration, and vision loss. Patients should be instructed to seek immediate medical attention if they experience sudden eye pain, redness, or visual changes.

Latanoprost is contraindicated in patients with known hypersensitivity to prostaglandin analogues or any component of the formulation. It should be used with caution in individuals with active ocular infections, a history of uveitis, or those who have experienced significant iris colour change with prior prostaglandin therapy.